Freedom Broker Maintains Buy on INmune Bio, Lowers Price Target to $2.5
Benzinga Newsdesk 3 hours ago
Analyst RatingsNewsPrice Target
Freedom Broker analyst Ilya Zubkov maintains INmune Bio (NASDAQ:INMB) with a Buy and lowers the price target from $4 to $2.5.
Freedom Broker analyst Ilya Zubkov maintains INmune Bio (NASDAQ:INMB) with a Buy and lowers the price target from $4 to $2.5.